• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

11.51 +0.21 (+1.86%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 154,991
Open 11.53
Bid (Size) 11.48 (100)
Ask (Size) 11.52 (100)
Prev. Close 11.30
Today's Range 11.20 - 11.70
52wk Range 4.110 - 14.00
Shares Outstanding 42,052,980
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
June 30, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
June 29, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+57.2%
+57.2%
1 Month
+24.8%
+24.8%
3 Month
+14.6%
+14.6%
6 Month
+53.5%
+53.5%
1 Year
+162.8%
+162.8%

More News

Read More
News headline image
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
June 29, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
June 12, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress ↗
May 07, 2026
Via Chartmill
News headline image
4DMT to Participate in Upcoming Investor Conferences
May 27, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy ↗
May 16, 2026
Via MarketBeat
News headline image
4DMT Announces New Employment Inducement Grants
May 15, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
May 07, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
May 04, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
March 18, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Meetings
March 16, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
February 19, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
February 13, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
February 09, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
January 17, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Provides Company Update and Anticipated Development Milestones for 2026
January 07, 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
December 17, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
December 12, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 08, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in 8th Annual Evercore Healthcare Conference
November 20, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Appoints Kristian Humer as Chief Financial Officer
November 17, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
November 14, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 10, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Jefferies 2025 London Healthcare Conference
November 06, 2025
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 11.51
When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 07/14/26 11:25 AM ET
What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 484.03M
How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
4D Molecular Therapeutics, Inc. - Common Stock has 484M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap